Publications 2021

Salib M, Girerd S, Girerd N, Marz W, Scharnagl H, Massy ZA, Leroy C, Duarte K, Holdaas H, Jardine AG, Schmieder RE, Fellstrom B, Lopez-Andres N, Rossignol P, Zannad F (2021)
Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial
Clin. Res. Cardiol.
DOI 10.1007/s00392-021-01898-9

Publications 2020

de Gonzalo-Calvo D, Martinez-Camblor P, Bar C, Duarte K, Girerd N, Fellstrom B, Schmieder RE, Jardine AG, Massy ZA, Holdaas H, Rossignol P, Zannad F, Thum T (2020)
Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids
Theranostics, 10 (19), 8665-8676
DOI 10.7150/thno.46123

Girerd S, Girerd N, Frimat L, Holdaas H, Jardine AG, Schmieder RE, Fellstrom B, Settembre N, Malikov S, Rossignol P, Zannad F, AURORA Study Grp French Clinical Res Infrastruct Ne (2020)
Arteriovenous fistula thrombosis is associated with increased all-cause and cardiovascular mortar in haemodialysis patients from the AURORA trial
Clin. Kidney J., 13 (1), 116-122
DOI 10.1093/ckj/sfz048

Haller MC, Wallisch C, Mjoen G, Holdaas H, Dunkler D, Heinze G, Oberbauer R (2020)
Predicting donor, recipient and graft survival in living donor kidney transplantation to inform pretransplant counselling: the donor and recipient linked iPREDICTLIVING tool - a retrospective study
Transpl. Int., 33 (7), 729-739
DOI 10.1111/tri.13580

Haugen AJ, Hallan S, Langberg NE, Dahle DO, Pihlstrom H, Birkeland KI, Reisaeter A, Midtvedt K, Hartmann A, Holdaas H, Mjoen G (2020)
Increased long-term risk for hypertension in kidney donors - a retrospective cohort study
Transpl. Int., 33 (5), 536-543
DOI 10.1111/tri.13576

Pihlstrom HK, Ueland T, Michelsen AE, Aukrust P, Gatti F, Hammarstrom C, Kasprzycka M, Wang JB, Haraldsen G, Mjoen G, Dahle DO, Midtvedt K, Eide IA, Hartmann A, Holdaas H (2020)
Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients
PLoS One, 15 (12), e0243759
DOI 10.1371/journal.pone.0243759

Publications 2019

Egeland EJ, Reisaeter AV, Robertsen I, Midtvedt K, Strom EH, Holdaas H, Hartmann A, Asberg A (2019)
High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study
Transpl. Int., 32 (3), 257-269
DOI 10.1111/tri.13356

Haugen AJ, Langberg NE, Dahle DO, Pihlstrom H, Birkeland KI, Reisaeter A, Midtvedt K, Hartmann A, Holdaas H, Mjoen G (2019)
Long-term risk for kidney donors with hypertension at donation - a retrospective cohort study
Transpl. Int., 32 (9), 960-964
DOI 10.1111/tri.13443

Holdaas H (2019)
B Cell Recruitment Follows Kidney Injury and Maladaptive Repair
Transplantation, 103 (8), 1529-1531
DOI 10.1097/TP.0000000000002658

Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Boltad N, Fellstrom B, Holdaas H, Asberg A, Bergan S, Teethe NT, Warren DJ (2019)
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
Ther. Drug Monit., 41 (1), 11-18
DOI 10.1097/FTD.0000000000000580

Mjoen G, Reisaeter A, Hartmann A, Dahle DO, Holdaas H (2019)
Regarding age-calibrated glomerular filtration rate
Kidney Int., 95 (1), 234-235
DOI 10.1016/j.kint.2018.10.003

Pihlstrom HK, Mjoen G, Mucha S, Franke A, Jardine A, Fellstrom B, Dahle DO, Holdaas H, Melum E (2019)
Genetic markers associated with long-term cardiovascular outcome in kidney transplant recipients
Am. J. Transplant., 19 (5), 1444-1451
DOI 10.1111/ajt.15191

Tunbridge M, Holdaas H, Jardine AG (2019)
Pulse Pressure: A Risk Factor for Renal Transplant Failure or a Useful Therapeutic Target?
Transplantation, 103 (4), 662-663
DOI 10.1097/TP.0000000000002441

Publications 2018

Abedini S, Goransson L, Cockburn E, Kilany S, Holdaas H (2018)
Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study
Transplant. Direct., 4 (2), e338
DOI 10.1097/TXD.0000000000000755

Garcia-Carro C, Dorje C, Asberg A, Midtvedt K, Scott H, Reinholt FP, Holdaas H, Reisaeter AV, Seron D (2018)
Kidney allograft subclinical rejection modulates systemic inflammation measured by C-reactive protein at 1year after transplantation
Clin. Transplant., 32 (3), e13196
DOI 10.1111/ctr.13196

Jardine AG, Hartmann A, Holdaas H (2018)
Long-term renal allograft survival: a quiet revolution
Kidney Int., 94 (5), 853-855
DOI 10.1016/j.kint.2018.08.005

Mafham MM, Staplin N, Emberson J, Haynes R, Herrington W, Reith C, Wanner C, Walker R, Cass A, Levin A, Fellstrom B, Jiang LX, Holdaas H, Kasiske B, Wheeler DC, Landray MJ, Baigent C, SHARP Collaborative Grp (2018)
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection
Nephrol. Dial. Transplant., 33 (2), 257-264
DOI 10.1093/ndt/gfw396

Mjoen G, Holdaas H (2018)
Mid- and Long-Term Health Risks in Living Kidney Donors
Ann. Intern. Med., 169 (4), 265
DOI 10.7326/L18-0340

Pedersen HL, Horvei KD, Thiyagarajan D, Norby GE, Seredkina N, Moroni G, Eilertsen GO, Holdaas H, Strom EH, Bakland G, Meroni PL, Rekvig OP (2018)
Lupus nephritis: low urinary DNase I levels reflect loss of renal DNase I and may be utilized as a biomarker of disease progression
J. Pathol. Clin. Res., 4 (3), 193-203
DOI 10.1002/cjp2.99

Solbu MD, Mjoen G, Mark PB, Holdaas H, Fellstrom B, Schmieder RE, Zannad F, Herrington WG, Jardine AG (2018)
Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study
Nephrol. Dial. Transplant., 33 (1), 102-112
DOI 10.1093/ndt/gfw360

Ussif A, Pihlstrom H, Pasch A, Holdaas H, Hartmann A, Smerud K, Asberg A (2018)
Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
BMC Nephrol., 19, 212
DOI 10.1186/s12882-018-1000-8

Publications 2017

Dahle DO, Grotmol T, Leivestad T, Hartmann A, Midtvedt K, Reisaeter AV, Mjoen G, Pihlstrom HK, Naess H, Holdaas H (2017)
Association Between Pretransplant Cancer and Survival in Kidney Transplant Recipients
Transplantation, 101 (10), 2599-2605
DOI 10.1097/TP.0000000000001659

de Fijter JW, Holdaas H, Oyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M, ELEVATE Study Grp (2017)
Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial
Am. J. Transplant., 17 (7), 1853-1867
DOI 10.1111/ajt.14186

Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Storset E, Gustavsen MT, Reisaeter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Asberg A (2017)
High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation
Transplantation, 101 (8), E273-E279
DOI 10.1097/TP.0000000000001796

Garcia-Carro C, Dorje C, Asberg A, Midtvedt K, Scott H, Reinholt FP, Holdaas H, Seron D, Reisaeter AV (2017)
Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies
Transplantation, 101 (6), 1410-1415
DOI 10.1097/TP.0000000000001216

Heldal K, Hartmann A, Lonning K, Leivestad T, Reisaeter AV, Line PD, Holdaas H, Midtvedt K (2017)
Should patients older than 65 years be offered a second kidney transplant?
BMC Nephrol., 18, 13
DOI 10.1186/s12882-016-0426-0

Holdaas H, de Fijter JW, Cruzado JM, Massari P, Nashan B, Kanellis J, Witzke O, Gutierrez-Dalmau A, Turkmen A, Wang Z, Lopez P, Bernhardt P, Kochuparampil J, van der Giet M, Murbraech K, ELEVATE Study Grp (2017)
Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study
Transplantation, 101 (10), 2612-2620
DOI 10.1097/TP.0000000000001739

Holdaas H, Mjoen G, Jardine AG (2017)
Belatacept: Where the BENEFITS Outweigh the Risk
Am. J. Kidney Dis., 69 (5), 561-563
DOI 10.1053/j.ajkd.2017.02.007

Lindahl JP, Massey RJ, Hartmann A, Aakhus S, Endresen K, Gunther A, Midtvedt K, Holdaas H, Leivestad T, Horneland R, Oyen O, Jenssen T (2017)
Cardiac Assessment of Patients With Type 1 Diabetes Median 10 Years After Successful Simultaneous Pancreas and Kidney Transplantation Compared With Living Donor Kidney Transplantation
Transplantation, 101 (6), 1261-1267
DOI 10.1097/TP.0000000000001274

Midtvedt K, Holdaas H, Bergan S, Asberg A (2017)
Costimulation Blockade: America First, Canada Second ... What About Norway?
Am. J. Transplant., 17 (8), 2230
DOI 10.1111/ajt.14351

Mjoen G, Holdaas H (2017)
Regarding "Obesity increases the risk of end-stage renal disease among living kidney donors"
Kidney Int., 91 (5), 1256
DOI 10.1016/j.kint.2017.01.034

Norby GE, Mjoen G, Bjorneklett R, Vikse BE, Holdaas H, Svarstad E, Aasarod K (2017)
Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry
Lupus, 26 (8), 881-885
DOI 10.1177/0961203316686700

Pihlstrom HK, Gatti F, Hammarstrom C, Eide IA, Kasprzycka M, Wang JB, Haraldsen G, Svensson MHS, Midtvedt K, Mjoen G, Dahle DO, Hartmann A, Holdaas H (2017)
Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study
Transpl. Int., 30 (8), 827-840
DOI 10.1111/tri.12973

Pihlstrom HK, Mjoen G, Mucha S, Haraldsen G, Franke A, Jardine A, Fellstrom B, Holdaas H, Melum E (2017)
Single Nucleotide Polymorphisms and Long-Term Clinical Outcome in Renal Transplant Patients: A Validation Study
Am. J. Transplant., 17 (2), 528-533
DOI 10.1111/ajt.13995

Rizvi SMH, Aagnes B, Holdaas H, Gude E, Boberg KM, Bjortuft O, Helsing P, Leivestad T, Moller B, Gjersvik P (2017)
Long-term Change in the Risk of Skin Cancer After Organ Transplantation A Population-Based Nationwide Cohort Study
JAMA Dermatol., 153 (12), 1270-1277
DOI 10.1001/jamadermatol.2017.2984

Torres IB, Reisaeter AV, Moreso F, Asberg A, Vidal M, Garcia-Carro C, Midtvedt K, Reinholt FP, Scott H, Castella E, Salcedo M, Dorje C, Sellares J, Azancot MA, Perello M, Holdaas H, Seron D (2017)
Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants
Transpl. Int., 30 (11), 1119-1131
DOI 10.1111/tri.13002

Wagner S, Apetrii M, Massy ZA, Kleber ME, Delgado GE, Scharnagel H, Maerz W, Metzger M, Rossignol P, Jardine A, Holdaas H, Fellstroem B, Schmieder R, Stengel B, Zannad F, Aurora Study Grp F-Crin INI-Crct Cardiovascular Ren (2017)
Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis
Free Radic. Res., 51 (1), 14-23
DOI 10.1080/10715762.2016.1241878

Publications 2016

Dahle DO, Asberg A, Hartmann A, Holdaas H, Bachtler M, Jenssen TG, Dionisi M, Pasch A (2016)
Serum Calcification Propensity Is a Strong and Independent Determinant of Cardiac and All-Cause Mortality in Kidney Transplant Recipients
Am. J. Transplant., 16 (1), 204-212
DOI 10.1111/ajt.13443

Dorje C, Reisaeter AV, Dahle DO, Mjoen G, Midtvedt K, Holdaas H, Flaa-Johnsen L, Syversveen T, Hartmann A, Jenssen T, Scott H, Reinholt FP (2016)
Total inflammation in early protocol kidney graft biopsies does not predict progression of fibrosis at one year post-transplant
Clin. Transplant., 30 (7), 802-809
DOI 10.1111/ctr.12753

Holdaas H, De Simone P, Zuckermann A (2016)
n Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
J. Transplant., 2016, 4369574
DOI 10.1155/2016/4369574

Lindahl JP, Hartmann A, Aakhus S, Endresen K, Midtvedt K, Holdaas H, Leivestad T, Horneland R, Yen O, Jenssen T (2016)
Long-term cardiovascular outcomes in type 1 diabetic patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation
Diabetologia, 59 (4), 844-852
DOI 10.1007/s00125-015-3853-8

Mjoen G, Holdaas H (2016)
Regarding long-term outcome after kidney donation
Transpl. Int., 29 (3), 381
DOI 10.1111/tri.12717

Mjoen G, Holdaas H (2016)
Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate
N. Engl. J. Med., 374 (21), 2094

Storset E, Asberg A, Hartmann A, Reisaeter AV, Holdaas H, Skauby M, Bergan S, Midtvedt K (2016)
Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience
Nephrology, 21 (10), 821-827
DOI 10.1111/nep.12738

Publications 2015

Aulie HA, Selvaag AM, Gunther A, Lilleby V, Molberg O, Hartmann A, Holdaas H, Flato B (2015)
Arterial haemodynamics and coronary artery calcification in adult patients with juvenile idiopathic arthritis
Ann. Rheum. Dis., 74 (8), 1515-1521
DOI 10.1136/annrheumdis-2013-204804

Dahle DO, Eide IA, Asberg A, Leivestad T, Holdaas H, Jenssen TG, Fagerland MW, Pihlstrom H, Mjoen G, Hartmann A (2015)
Aortic Stiffness in a Mortality Risk Calculator for Kidney Transplant Recipients
Transplantation, 99 (8), 1730-1737
DOI 10.1097/TP.0000000000000660

Dorje C, Mjoen G, Strom EH, Holdaas H, Jenssen T, Oyen O, Akkok CA, Cvancarova M, Midtvedt K, Reisaeter AV (2015)
One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts
Clin. Transplant., 29 (3), 268-276
DOI 10.1111/ctr.12515

Drechsler C, Pihlstrom H, Meinitzer A, Pilz S, Tomaschitz A, Abedini S, Fellstrom B, Jardine AG, Wanner C, Marz W, Holdaas H (2015)
Homoarginine and Clinical Outcomes in Renal Transplant Recipients Results From the Assessment of Lescol in Renal Transplantation Study
Transplantation, 99 (7), 1470-1476
DOI 10.1097/TP.0000000000000568

Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A, de Lemos J, Blazing M, Murphy S, Downs JR, Gotto A, Clearfield M et al. (2015)
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
Lancet, 385 (9976), 1397-1405
DOI 10.1016/S0140-6736(14)61368-4

Holdaas H, Potena L, Saliba F (2015)
mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?
Transplant. Rev., 29 (2), 93-102
DOI 10.1016/j.trre.2014.08.003

Mjoen G, Holdaas H (2015)
Selecting Appropriate Controls for Kidney Donors
Am. J. Transplant., 15 (1), 286
DOI 10.1111/ajt.13016

Mjoen G, Holdaas H (2015)
Regarding 'Long-term risks for kidney donors' Reply
Kidney Int., 87 (3), 660
DOI 10.1038/ki.2014.400

Mjornstedt L, Sorensen SS, von zur Muhlen B, Jespersen B, Hansen JM, Bistrup C, Andersson H, Gustafsson B, Solbu D, Holdaas H (2015)
Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation
Transpl. Int., 28 (1), 42-51
DOI 10.1111/tri.12437

Murbraech K, Massey R, Undset LH, Midtvedt K, Holdaas H, Aakhus S (2015)
Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients - a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial
Clin. Transplant., 29 (8), 678-684
DOI 10.1111/ctr.12565

Pihlstrom H, Dahle DO, Mjoen G, Pilz S, Marz W, Abedini S, Holme I, Fellstrom B, Jardine AG, Holdaas H (2015)
Increased Risk of All-Cause Mortality and Renal Graft Loss in Stable Renal Transplant Recipients With Hyperparathyroidism
Transplantation, 99 (2), 351-359
DOI 10.1097/TP.0000000000000583

Publications 2014

Apeland T, Holdaas H, Mansoor MA (2014)
Kidney donors and kidney transplants have abnormal aminothiol redox status, and are at increased risk of oxidative stress and reduced redox buffer capacity
Clin. Biochem., 47 (6), 378-382
DOI 10.1016/j.clinbiochem.2014.02.003

Dahle DO, Jenssen T, Holdaas H, Asberg A, Soveri I, Holme I, Mjoen G, Eide IA, Pihlstrom H, Doerje C, Halden TAS, Hartmann A (2014)
Uric acid and clinical correlates of endothelial function in kidney transplant recipients
Clin. Transplant., 28 (10), 1167-1176
DOI 10.1111/ctr.12435

Dahle DO, Jenssen T, Holdaas H, Leivestad T, Vardal M, Mjoen G, Reisaeter AV, Toft I, Hartmann A (2014)
Uric acid has a J-shaped association with cardiovascular and all-cause mortality in kidney transplant recipients
Clin. Transplant., 28 (1), 134-140
DOI 10.1111/ctr.12290

Evenepoel P, Cooper K, Holdaas H, Messa P, Mourad G, Olgaard K, Rutkowski B, Schaefer H, Deng H, Torregrosa JV, Wuthrich RP, Yue S (2014)
A Randomized Study Evaluating Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients With Persistent Hyperparathyroidism
Am. J. Transplant., 14 (11), 2545-2555
DOI 10.1111/ajt.12911

Fellstrom B, Holdaas H, Jardine A (2014)
Functional Cardiopulmonary Exercise Testing in Potential Renal Transplant Recipients
J. Am. Soc. Nephrol., 25 (1), 8-9
DOI 10.1681/ASN.2013090996

Holdaas H, Jardine AG (2014)
BP Targets in Renal Transplant Recipients: Too High or Too Low?
J. Am. Soc. Nephrol., 25 (7), 1371-1373
DOI 10.1681/ASN.2014020177

Holdaas H, Mjoen G (2014)
Long-Term Risks of Kidney Donation: Age Known
Am. J. Transplant., 14 (11), 2671-2672
DOI 10.1111/ajt.12971

Lindahl JP, Reinholt FP, Eide IA, Hartmann A, Midtvedt K, Holdaas H, Dorg LT, Reine TM, Kolset SO, Horneland R, Oyen O, Brabrand K, Jenssen T (2014)
In patients with type 1 diabetes simultaneous pancreas and kidney transplantation preserves long-term kidney graft ultrastructure and function better than transplantation of kidney alone
Diabetologia, 57 (11), 2357-2365
DOI 10.1007/s00125-014-3353-2

Mjoen G, Hallan S, Dekker FW, Holdaas H (2014)
Kidney donors at increased risk? Additional studies are needed Reply
Kidney Int., 86 (3), 650
DOI 10.1038/ki.2014.148

Mjoen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Oyen O, Reisaeter A, Pfeffer P, Jenssen T, Leivestad T, Line PD, Ovrehus M, Dale DO, PihIstrom H, Holme I, Dekker FW, Holdaas H (2014)
Long-term risks for kidney donors
Kidney Int., 86 (1), 162-167
DOI 10.1038/ki.2013.460

Mjoen G, Hallan S, Holdaas H (2014)
The importance of selecting controls in kidney donor outcome studies Reply
Kidney Int., 85 (5), 1241-1242
DOI 10.1038/ki.2014.37

Mjoen G, Holdaas H (2014)
Long-term risks for kidney donors Reply
Kidney Int., 86 (2), 447
DOI 10.1038/ki.2014.149

Murbraech K, Holdaas H, Massey R, Undset LH, Aakhus S (2014)
Cardiac Response to Early Conversion from Calcineurin Inhibitor to Everolimus in Renal Transplant Recipients: An Echocardiographic Substudy of the Randomized Controlled CENTRAL Trial
Transplantation, 97 (2), 184-188
DOI 10.1097/TP.0b013e3182a92728

Pihlstrom H, Mjoen G, Dahle DO, Pilz S, Midtvedt K, Marz W, Abedini S, Holme I, Fellstrom B, Jardine A, Holdaas H (2014)
Symmetric Dimethylarginine as Predictor of Graft loss and All-Cause Mortality in Renal Transplant Recipients
Transplantation, 98 (11), 1219-1225
DOI 10.1097/TP.0000000000000205

Robertsen I, Asberg A, Granseth T, Vethe NT, Akhlaghi F, Ghareeb M, Molden E, Reier-Nilsen M, Holdaas H, Midtvedt K (2014)
More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients
Transplantation, 97 (12), 1266-1271
DOI 10.1097/01.TP.0000443225.66960.7e

van der Giet M, Cruzado JM, de Fijter JW, Holdaas H, Wang ZL, Speziale A, Junge G (2014)
ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus
Open Access J. Clin. Trials, 6, 17-27
DOI 10.2147/OAJCT.S59549

Publications 2013

Dahle DO, Midtvedt K, Hartmann A, Jenssen T, Holdaas H, Mjoen G, Leivestad T, Asberg A (2013)
Endothelial Dysfunction Is Associated With Graft Loss in Renal Transplant Recipients
Transplantation, 95 (5), 733-739
DOI 10.1097/TP.0b013e31827d6312

Dorje C, Midtvedt K, Holdaas H, Naper C, Strom EH, Oyen O, Leivestad T, Aronsen T, Jenssen T, Flaa-Johnsen L, Lindahl JP, Hartmann A, Reisaeter AV (2013)
Early Versus Late Acute Antibody-Mediated Rejection in Renal Transplant Recipients
Transplantation, 96 (1), 79-84
DOI 10.1097/TP.0b013e31829434d4

Holme I, Fellstrom BC, Jardine AG, Hartmann A, Holdaas H (2013)
Model Comparisons of Competing Risk and Recurrent Events for Graft Failure in Renal Transplant Recipients
Clin. J. Am. Soc. Nephrol., 8 (2), 241-247
DOI 10.2215/CJN.03760412

Lindahl JP, Hartmann A, Horneland R, Holdaas H, Reisaeter AV, Midtvedt K, Leivestad T, Oyen O, Jenssen T (2013)
Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease
Diabetologia, 56 (6), 1364-1371
DOI 10.1007/s00125-013-2888-y

Schjelderup P, Dahle DO, Holdaas H, Mjoen G, Nordby G, Abedini S, Jardine A, Fellstrom B, Svensson M (2013)
Anemia is a predictor of graft loss but not cardiovascular events and all-cause mortality in renal transplant recipients: follow-up data from the ALERT study
Clin. Transplant., 27 (6), E636-E643
DOI 10.1111/ctr.12220

Schneider A, Jardine AG, Schneider MP, Holdaas H, Holme I, Fellstroem BC, Zannad F, Schmieder RE, AURORA Study Grp (2013)
Determinants of Cardiovascular Risk in Haemodialysis Patients: Post hoc Analyses of the AURORA Study
Am. J. Nephrol., 37 (2), 144-151
DOI 10.1159/000346710

Soveri I, Snyder J, Holdaas H, Holme I, Jardine AG, L'Italien GJ, Fellstrom B (2013)
The External Validation of the Cardiovascular Risk Equation for Renal Transplant Recipients: Applications to BENEFIT and BENEFIT-EXT Trials
Transplantation, 95 (1), 142-147
DOI 10.1097/TP.0b013e31827722c9

Tonelli MA, Wanner C, Cass A, Garg AX, Holdaas H, Jardine AG, Jiang LX, Kronenberg F, Parekh RS, Shoji T, Walker RJ, Kasiske BL, Wheeler DC, Upadhyay A, Balk EM, Earley A, Haynes S, Lamont J (2013)
Introduction: The case for updating and context
Kidney Int. Suppl., 3 (3), 266-+
DOI 10.1038/kisup.2013.32

Publications 2012

Hartmann A, Jenssen T, Holdaas H (2012)
Diabetes, chronic kidney disease and cancer risk
Nephrol. Dial. Transplant., 27 (8), 3018-3020
DOI 10.1093/ndt/gfs175

Holdaas H, Jardine A (2012)
Do patients with CKD benefit from lipid-lowering therapy?
Nat. Rev. Nephrol., 8 (12), 684-685
DOI 10.1038/nrneph.2012.240

Holdaas H, Midtvedt K, Asberg A (2012)
A drug safety evaluation of everolimus in kidney transplantation
Expert Opin. Drug Saf., 11 (6), 1013-1022
DOI 10.1517/14740338.2012.722993

Holme I, Fellstrom BC, Jardin AG, Schmieder RE, Zannad F, Holdaas H (2012)
Prognostic model for total mortality in patients with haemodialysis from the Assessments of Survival and Cardiovascular Events (AURORA) study
J. Intern. Med., 271 (5), 463-471
DOI 10.1111/j.1365-2796.2011.02435.x

Loftheim H, Midtvedt K, Hartmann A, Reister AV, Falck P, Holdaas H, Jenssen T, Reubsaet L, Asberg A (2012)
Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients
Transplant. Res., 1, 9
DOI 10.1186/2047-1440-1-9

Mjoen G, Reisaeter A, Hallan S, Line PD, Hartmann A, Midtvedt K, Foss A, Dahle DO, Holdaas H (2012)
Overall and cardiovascular mortality in Norwegian kidney donors compared to the background population
Nephrol. Dial. Transplant., 27 (1), 443-447
DOI 10.1093/ndt/gfr303

Mjornstedt L, Sorensen SS, von zur Muhlen B, Jespersen B, Hansen JM, Bistrup C, Andersson H, Gustafsson B, Undset LH, Fagertun H, Solbu D, Holdaas H (2012)
Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation
Am. J. Transplant., 12 (10), 2744-2753
DOI 10.1111/j.1600-6143.2012.04162.x

Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellstrom B (2012)
Graft loss risk in renal transplant recipients with metabolic syndrome: subgroup analyses of the ALERT trial
J. Nephrol., 25 (2), 245-254
DOI 10.5301/JN.2011.8450

Soveri I, Holme I, Holdaas H, Budde K, Jardine AG, Fellstrom B (2012)
A Cardiovascular Risk Calculator for Renal Transplant Recipients
Transplantation, 94 (1), 57-62
DOI 10.1097/TP.0b013e3182516cdc

Svensson M, Dahle DO, Mjoen G, Weihrauch G, Scharnagl H, Dobnig H, Marz W, Jardine A, Fellstrom B, Holdaas H (2012)
Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study
Nephrol. Dial. Transplant., 27 (6), 2571-2575
DOI 10.1093/ndt/gfr694

Svensson M, Jardine A, Fellstrom B, Holdaas H (2012)
Prevention of cardiovascular disease after renal transplantation
Curr. Opin. Organ Transpl., 17 (4), 393-400
DOI 10.1097/MOT.0b013e3283560a3b

Publications 2011

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang LX, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V et al. (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Lancet, 377 (9784), 2181-2192
DOI 10.1016/S0140-6736(11)60739-3

Brabrand K, Holdaas H, Gunther A, Midtvedt K (2011)
Spontaneous regression of initially elevated peak systolic velocity in renal transplant artery
Transpl. Int., 24 (6), 555-559
DOI 10.1111/j.1432-2277.2011.01233.x

Campistol JM, de Fijter JW, Nashan B, Holdaas H, Vitko S, Legendre C (2011)
Everolimus and Long-Term Outcomes in Renal Transplantation
Transplantation, 92 (3 S), S3-S26
DOI 10.1097/TP.0b013e3182230900

Dahle DO, Mjoen G, Oqvist B, Scharnagl H, Weihrauch G, Grammer T, Marz W, Abedini S, Norby GE, Holme I, Fellstrom B, Jardine A, Holdaas H (2011)
Inflammation-associated graft loss in renal transplant recipients
Nephrol. Dial. Transplant., 26 (11), 3756-3761
DOI 10.1093/ndt/gfr163

Holdaas H, Holme I, Schmieder RE, Jardine AG, Zannad F, Norby GE, Fellstrom BC, AURORA Study Grp (2011)
Rosuvastatin in Diabetic Hemodialysis Patients
J. Am. Soc. Nephrol., 22 (7), 1335-1341
DOI 10.1681/ASN.2010090987

Holdaas H, Rostaing L, Seron D, Cole E, Chapman J, Fellstrom B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ, ASCERTAIN Investigators (2011)
Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study
Transplantation, 92 (4), 410-418
DOI 10.1097/TP.0b013e318224c12d

Marz W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, Stojakovic T, Scharnagl H, Winkler K, Holme I, Holdaas H, Wanner C, German Diabetes Dialysis Study Inv (2011)
Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis
Clin. J. Am. Soc. Nephrol., 6 (6), 1316-1325
DOI 10.2215/CJN.09121010

Midtvedt K, Holdaas H (2011)
Belatacept: BENEFIT to the kidney?
Am. J. Transplant., 11 (3), 633
DOI 10.1111/j.1600-6143.2010.03411.x

Mjoen G, Midtvedt K, Holme I, Oyen O, Fauchald P, Bergrem H, Holdaas H (2011)
One- and five-year follow-ups on blood pressure and renal function in kidney donors
Transpl. Int., 24 (1), 73-77
DOI 10.1111/j.1432-2277.2010.01148.x

Mjoen G, Oyen O, Midtvedt K, Dahle DO, Norby G, Holdaas H (2011)
Age, gender, and body mass index are associated with renal function after kidney donation
Clin. Transplant., 25 (6), E579-E583
DOI 10.1111/j.1399-0012.2011.01503.x

Mjoen G, Stavem K, Westlie L, Midtvedt K, Fauchald P, Norby G, Holdaas H (2011)
Quality of Life in Kidney Donors
Am. J. Transplant., 11 (6), 1315-1319
DOI 10.1111/j.1600-6143.2011.03517.x

Norby GE, Gunther A, Mjoen G, Andersen R, Dolgos S, Hartmann A, Holdaas H (2011)
Prevalence and risk factors for coronary artery calcification following kidney transplantation for systemic lupus erythematosus
RHEUMATOLOGY, 50 (9), 1659-1664
DOI 10.1093/rheumatology/ker186

Norby GE, Leivestad T, Mjoen G, Hartmann A, Midtvedt K, Gran JT, Holdaas H (2011)
Premature Cardiovascular Disease in Patients With Systemic Lupus Erythematosus Influences Survival After Renal Transplantation
Arthritis Rheum., 63 (3), 733-737
DOI 10.1002/art.30184

Publications 2010

Abedini S, Meinitzer A, Holme I, Marz W, Weihrauch G, Fellstrom B, Jardine A, Holdaas H (2010)
Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients
Kidney Int., 77 (1), 44-50
DOI 10.1038/ki.2009.382

Asberg A, Falck P, Undset LH, Dorje C, Holdaas H, Hartmann A, Midtvedt K (2010)
Computer-Assisted Cyclosporine Dosing Performs Better Than Traditional Dosing in Renal Transplant Recipients: Results of a Pilot Study
Ther. Drug Monit., 32 (2), 152-158
DOI 10.1097/FTD.0b013e3181d3f822

Gude E, Gullestad L, Arora S, Simonsen S, Hoel I, Hartmann A, Holdaas H, Fiane AE, Geiran OR, Andreassen AK (2010)
Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation
J. Heart Lung Transplant., 29 (6), 641-647
DOI 10.1016/j.healun.2010.01.005

Holme I, Fayyad R, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Holdaas H, Pedersen TR, Incremental Decrease End Points Ag (2010)
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial
J. Intern. Med., 267 (6), 567-575
DOI 10.1111/j.1365-2796.2009.02176.x

Holme I, Fellstrom B, Jardine A, Holdaas H (2010)
Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients
Atherosclerosis, 208 (1), 234-239
DOI 10.1016/j.atherosclerosis.2009.06.020

McQuarrie EP, Fellstrom BC, Holdaas H, Jardine AG (2010)
CARDIOVASCULAR DISEASE IN RENAL TRANSPLANT RECIPIENTS
J. Ren. Care, 36 S1, 136-145
DOI 10.1111/j.1755-6686.2010.00160.x

Mjoen G, Holdaas H, Pfeffer P, Line PD, Oyen O (2010)
Minimally invasive living donor nephrectomy - introduction of hand-assistance
Transpl. Int., 23 (10), 1008-1014
DOI 10.1111/j.1432-2277.2010.01087.x

Norby GE, Strom EH, Midtvedt K, Hartmann A, Gilboe IM, Leivestad T, Stenstrom J, Holdaas H (2010)
Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study
Ann. Rheum. Dis., 69 (8), 1484-1487
DOI 10.1136/ard.2009.122796

Aasebo W, Midtvedt K, Valderhaug TG, Leivestad T, Hartmann A, Reisaeter AV, Jenssen T, Holdaas H (2010)
Impaired glucose homeostasis in renal transplant recipients receiving basiliximab
Nephrol. Dial. Transplant., 25 (4), 1289-1293
DOI 10.1093/ndt/gfp617

Publications 2009

Abedini S, Holme I, Fellstrom B, Jardine A, Cole E, Maes B, Holdaas H, ALERT Study Grp (2009)
Cerebrovascular Events in Renal Transplant Recipients
Transplantation, 87 (1), 112-117
DOI 10.1097/TP.0b013e31818bfce8

Abedini S, Holme I, Marz W, Weihrauch G, Fellstrom B, Jardine A, Cole E, Maes B, Neumayer HH, Gronhagen-Riska C, Ambuhl P, Holdaas H, Alert Study Group (2009)
Inflammation in Renal Transplantation
Clin. J. Am. Soc. Nephrol., 4 (7), 1246-1254
DOI 10.2215/CJN.00930209

Bremer S, Vethe NT, Rootwelt H, Jorgensen PF, Stenstrom J, Holdaas H, Midtvedt K, Bergan S (2009)
Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
J. Transl. Med., 7, 64
DOI 10.1186/1479-5876-7-64

Falck P, Midtvedt K, Van Le TT, Storehagen L, Holdaas H, Hartmann A, Asberg A (2009)
A Population Pharmacokinetic Model of Ciclosporin Applicable for Assisting Dose Management of Kidney Transplant Recipients
Clin. Pharmacokinet., 48 (9), 615-623
DOI 10.2165/11313380-000000000-00000

Fellstrom B, Holdaas H, Jardine AG, Svensson MK, Gottlow M, Schmieder RE, Zannad F, AURORA Study Grp (2009)
Cardiovascular disease in patients with renal disease: the role of statins
Curr. Med. Res. Opin., 25 (1), 271-285
DOI 10.1185/03007990802622064

Fellstrom B, Jardine A, Holdaas H, AURORA Executive Steering Comm (2009)
Rosuvastatin in Patients Undergoing Hemodialysis REPLY
N. Engl. J. Med., 361 (1), 94-95

Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M et al. (2009)
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
N. Engl. J. Med., 360 (14), 1395-1407
DOI 10.1056/NEJMoa0810177

Midtvedt K, Bitter J, Dorje C, Bjorneklett R, Holdaas H (2009)
Belatacept as Immuno suppression in Patient With Recurrence of Hemolytic Uremic Syndrome After Renal Transplantation
Transplantation, 87 (12), 1901-1903
DOI 10.1097/TP.0b013e3181a991ca

Mjoen G, Oyen O, Holdaas H, Midtvedt K, Line PD (2009)
Morbidity and Mortality in 1022 Consecutive Living Donor Nephrectomies: Benefits of a Living Donor Registry
Transplantation, 88 (11), 1273-1279
DOI 10.1097/TP.0b013e3181bb44fd

Norby GE, Holme I, Fellstrom B, Jardine A, Cole E, Abedini S, Holdaas H, Assessment Lescol Renal Transplant (2009)
Effect of Fluvastatin on Cardiac Outcomes in Kidney Transplant Patients With Systemic Lupus Erythematosus A Randomized Placebo-Controlled Study
Arthritis Rheum., 60 (4), 1060-1064
DOI 10.1002/art.24379

Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellstrom B (2009)
Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment
Clin. Transplant., 23 (6), 914-920
DOI 10.1111/j.1399-0012.2009.01025.x

Valderhaug TG, Jenssen T, Hartmann A, Midtvedt K, Holdaas H, Reisaeter AV, Hjelmesaeth J (2009)
Fasting Plasma Glucose and Glycosylated Hemoglobin in the Screening for Diabetes Mellitus After Renal Transplantation
Transplantation, 88 (3), 429-434
DOI 10.1097/TP.0b013e3181af1f53

Witczak BJ, Leivestad T, Line PD, Holdaas H, Reisaeter AV, Jenssen TG, Midtvedt K, Bitter J, Hartmann A (2009)
Experience From an Active Preemptive Kidney Transplantation Program-809 Cases Revisited
Transplantation, 88 (5), 672-677
DOI 10.1097/TP.0b013e3181b27b7e

Publications 2008

Falck P, Vethe NT, Asberg A, Midtvedt K, Bergan S, Reubsaet JLE, Holdaas H (2008)
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients
Nephrol. Dial. Transplant., 23 (3), 1048-1053
DOI 10.1093/ndt/gfm632

Foss A, Gunther A, Line PD, Brabrand K, Holdaas H, Hartmann A, Midtvedt K (2008)
Long-term clinical outcome of paediatric kidneys transplanted to adults
Nephrol. Dial. Transplant., 23 (2), 726-729
DOI 10.1093/ndt/gfm826

Gunther A, Foss A, Holdaas H, Brabrand K, Hartmann A, Line PD, Midtvedt K (2008)
Increased peak systolic velocity in the renal artery of paediatric kidneys transplanted to adult recipients
Nephrol. Dial. Transplant., 23 (12), 4041-4043
DOI 10.1093/ndt/gfn358

Holdaas H (2008)
Statin therapy for prevention of coronary artery disease. The earlier the better or the longer the better?
Eur. Heart J., 29 (4), 425-426
DOI 10.1093/eurheartj/ehm628

Holdaas H, Bentdal O, Pfeffer P, Mjornstedt L, Solbu D, Midtvedt K (2008)
Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study
Clin. Transplant., 22 (3), 366-371
DOI 10.1111/j.1399-0012.2008.00795.x

Publications 2007

Ekberg H, Kyllonen L, Madsen S, Grave G, Solbu D, Holdaas H (2007)
Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients
Transplantation, 83 (3), 282-289
DOI 10.1097/01.tp.0000251923.14697.f5

Ekberg H, Kyllonen L, Madsen S, Grave G, Solbu D, Holdaas H (2007)
Clinicians underestimate gastrointestinal symptoms and overestimate quality of life in renal transplant recipients: A multinational survey of nephrologists
Transplantation, 84 (8), 1052-1054
DOI 10.1097/01.tp.0000284983.89207.1a

Fellstrom B, Holdaas H, Jardine AG, Rose H, Schmieder R, Wilpshaar W, Zannad F, AURORA Study Grp (2007)
Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study
Kidney Blood Pressure Res., 30 (5), 314-322
DOI 10.1159/000106803

Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J (2007)
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: A pooled analysis of double-blind, randomized trials
Int. J. Cardiol., 117 (1), 64-74
DOI 10.1016/j.ijcard.2006.06.003

Singer JB, Holdaas H, Jardine AG, Fellstrom B, Os I, Bermann G, Meyer JM, ALERT Study Investigators (2007)
Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients
J. Lipid Res., 48 (9), 2072-2078
DOI 10.1194/jlr.M700076-JLR200

Publications 2006

Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A (2006)
Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients
Transplantation, 82 (1), 62-68
DOI 10.1097/01.tp.0000225803.04995.2b

Fellstrom B, Abedini S, Holdaas H, Jardine AG, Staffler B, Gimpelewicz C, ALERT Study Grp (2006)
No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study
Clin. Transplant., 20 (6), 732-739
DOI 10.1111/j.1399-0012.2006.00555.x

Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, Jenssen T (2006)
The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events
Kidney Int., 69 (3), 588-595
DOI 10.1038/sj.ki.5000116

Holdaas H, Hagen E, Asberg A, Lund K, Hartman A, Vaidyanathan S, Prasad P, He YL, Yeh CM, Bigler H, Rouilly M, Denouel J (2006)
Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients
Int. J. Clin. Pharmacol. Ther., 44 (4), 163-171

Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J (2006)
The renal safety profile of fluvastatin: Results of a pooled analysis
Ren. Fail., 28 (6), 487-492
DOI 10.1080/08860220600781260

Oien CM, Reisaeter AV, Os I, Jardine A, Fellstrom B, Holdaas H (2006)
Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study
Clin. Transplant., 20 (3), 374-382
DOI 10.1111/j.1399-0012.2006.00496.x

Soveri I, Holdaas H, Jardine A, Gimpelewicz C, Staffler B, Fellstrom B (2006)
Renal transplant dysfunction - importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality
Nephrol. Dial. Transplant., 21 (8), 2282-2289
DOI 10.1093/ndt/gfl095

Publications 2005

Corsini A, Holdaas H (2005)
Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation
Ren. Fail., 27 (3), 259-273
DOI 10.1081/JDI-200056623

Fellstrom B, Holdaas H, Jardine AG, Nyberg G, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Staffler B, Pedersen TR, Assessment Lescol Renal Transplant (2005)
Risk factors for reaching renal Endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) trial
Transplantation, 79 (2), 205-212
DOI 10.1097/01.TP.0000147338.34323.12

Fellstrom B, Jardine AG, Soveri I, Cole E, Gronhagen-Riska C, Neumayer HH, Maes B, Gimpelewicz C, Holdaas H (2005)
Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: Experience from the Assessment of Lescol in Renal Transplantation trial
Transplantation, 79 (9), 1160-1163
DOI 10.1097/01.TP.0000160764.35083.B8

Fellstrom B, Jardine AG, Soveri I, Cole E, Neumayer HH, Maes B, Gimpelewicz C, Holdaas H, ALERT Study Grp (2005)
Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation
Am. J. Transplant., 5 (8), 1986-1991
DOI 10.1111/j.1600-6143.2005.00983.x

Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, Wilpshaar W, AURORA Study Grp (2005)
Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study
Curr. Control Trials Cardivasc. Med., 6, 9
DOI 10.1186/1468-6708-6-9

Hermann M, Asberg A, Christensen H, Reubsaet JLE, Holdaas H, Hartmann A (2005)
Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients
Eur. J. Clin. Pharmacol., 61 (1), 59-62
DOI 10.1007/s00228-004-0874-5

Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl P, Hartmann A, Staffler B, Jardine AG, ALERT Study Investigators (2005)
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study
Am. J. Transplant., 5 (12), 2929-2936
DOI 10.1111/j.1600-6143.2005.01105.x

Holdaas H, Fellstrom B, Jardine AG, ALERT Study Grp (2005)
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: Lessons to be learnt from the assessment of Lescol (R) in renal transplantation (ALERT) trial
Am. J. Transplant., 5 (6), 1574-1575
DOI 10.1111/j.1600-6143.2005.00909.x

Holdaas H, Fellstrom B, Jardine AG, Nyberg G, Grohagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Logan JO, Staffler B, Gimpelewicz C, ALERT Study Grp (2005)
Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation
Nephrol. Dial. Transplant., 20 (5), 974-980
DOI 10.1093/ndt/gfh735

Jardine AG, Fellstrom B, Logan JO, Cole E, Nyberg G, Gronhagen-Riska C, Madsen S, Neumayer HH, Maes B, Ambuhl P, Olsson AG, Pedersen T, Holdaas H (2005)
Cardiovascular risk and renal transplantation: Post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) study
Am. J. Kidney Dis., 46 (3), 529-536
DOI 10.1053/j.ajkd.2005.05.014

Lemahieu WPD, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD (2005)
Combined therapy with atorvastatin and calcineurin inhibitors: No interactions with tacrolimus
Am. J. Transplant., 5 (9), 2236-2243
DOI 10.1111/j.1600-6143.2005.01005.x

Publications 2004

Fellstrom B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Logan JO, Pedersen TR, ALERT Study Investigators (2004)
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial
Kidney Int., 66 (4), 1549-1555
DOI 10.1111/j.1523-1755.2004.00919.x

Hermann M, Asberg A, Christensen H, Holdaas H, Hartmann A, Reubsaet JLE (2004)
Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients
Clin. Pharmacol. Ther., 76 (4), 388-391
DOI 10.1016/j.clpt.2004.07.008

Jardine AG, Holdaas H, Fellstrom B, Cole E, Nyberg G, Gronhagen-Riska C, Madsen S, Neumayer HH, Maes B, Ambuhl P, Olsson AG, Holme I, Fauchald P, Gimpelwicz C, Pedersen TR, ALERT Study (2004)
Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: Post-hoc subgroup analyses of the ALERT study
Am. J. Transplant., 4 (6), 988-995
DOI 10.1111/j.1600-6143.2004.00445.x

Os I, Holdaas H (2004)
Diabetes og høyt blodtrykk
In Diabeteshåndboken, Gyldendal akademisk, Oslo, s. 256-269
BIBSYS 041965264

Publications 2003

Asberg A, Holdaas H, Jardine AG, Edvardsen C, Hartmann A (2003)
Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation
Clin. Transplant., 17 (4), 385-390
DOI 10.1034/j.1399-0012.2003.00063.x

Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JPD, Stein EA (2003)
Risk for myopathy with statin therapy in high-risk patients
Arch. Intern. Med., 163 (5), 553-564
DOI 10.1001/archinte.163.5.553

Fellstrom BC, Holdaas H, Jardine AG (2003)
Why do we need a statin trial in hemodialysis patients?
Kidney Int., 63 84, S204-S206
DOI 10.1046/j.1523-1755.63.s84.10.x

Hartmann A, Fauchald P, Westlie L, Brekke IB, Holdaas H (2003)
The risk of living kidney donation
Nephrol. Dial. Transplant., 18 (5), 871-873
DOI 10.1093/ndt/gfg069

Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR, ALERT Study Investigators (2003)
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
Lancet, 361 (9374), 2024-2031
DOI 10.1016/S0140-6736(03)13638-0

Holdaas H, Fellstrøm B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR (2003)
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
In Lancet, Lancet Ltd., London, 361(2003)9374, s.2024-31
BIBSYS 041716655

Jakobsen A, Holdaas H, Leivestad T (2003)
Ethics and safety of living kidney donation
Transplant. Proc., 35 (3), 1177-1178
DOI 10.1016/S0041-1345(03)00136-2

Westlie L, Leivestad T, Holdaas H, Lien B, Meyer K, Fauchald P (2003)
Report from the Norwegian National Hospitals Living Donor Registry: One-year data, January 1, 2002
Transplant. Proc., 35 (2), 777-778
DOI 10.1016/S0041-1345(03)00039-3

Publications 2001

Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H (2001)
Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients
Am. J. Transplant., 1 (4), 382-386
DOI 10.1034/j.1600-6143.2001.10415.x

Asberg A, Hartmann A, Fjeldsa E, Holdaas H (2001)
Atorvastatin improves endothelial function in renal-transplant recipients
Nephrol. Dial. Transplant., 16 (9), 1920-1924
DOI 10.1093/ndt/16.9.1920

Holdaas H, Fellstrom B, Holme I, Nyberg G, Fauchald P, Jardine A, Gronhagen-Riska C, Madser S, Neumayer HH, Cole E, Maes B, Weinreich T, Olsson AG, Pedersen TR, Benghozi R, Hartmann A, ALERT Study Grp (2001)
Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol (R) in Renal Transplantation) study design and baseline data
J. Cardiovasc. Risk, 8 (2), 63-71
DOI 10.1097/00043798-200104000-00002

Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B, Hammad A, Holme I, Isoniemi H, Moore R, Rowe PA, Sweny P, Talbot DA, Wadstrom J, Ostraat O (2001)
Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial
Kidney Int., 60 (5), 1990-1997
DOI 10.1046/j.1523-1755.2001.00010.x

Linde T, Ekberg H, Forslund T, Furuland H, Holdaas H, Nyberg G, Tyden G, Wahlberg J, Danielson BG (2001)
The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome
Transplantation, 71 (1), 79-82
DOI 10.1097/00007890-200101150-00013

Midtvedt K, Hartmann A, Foss A, Fauchald P, Nordal KP, Rootwelt K, Holdaas H (2001)
Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril
Transplantation, 72 (11), 1787-1792
DOI 10.1097/00007890-200112150-00013

Midtvedt K, Hartmann A, Holdaas H, Fauchald P (2001)
Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double-blind randomised comparative trial
Clin. Transplant., 15 (6), 426-431
DOI 10.1034/j.1399-0012.2001.150611.x

Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL, Foss A, Fauchald P, Holdaas H (2001)
Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: A prospective randomized double-blind study
Transplantation, 72 (1), 107-111
DOI 10.1097/00007890-200107150-00021

Publications 1999

Holdaas H (1999)
Den sosiale strukturen i norsk nefrologi: jubileumshefte til 25 års-jubileet
Norsk nyremedisinsk forening, Kristiansand, 12 s.
BIBSYS 060545968

Jardine A, Holdaas H (1999)
Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience
J. Clin. Pharm. Ther., 24 (6), 397-408
DOI 10.1046/j.1365-2710.1999.00252.x

Publications 1998

Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P (1998)
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy
Nephrol. Dial. Transplant., 13 (12), 3096-3102
DOI 10.1093/ndt/13.12.3096

Publications 1996

Hartmann A, Andreassen AK, Holdaas H, Simonsen S, Geiran O, Berg KJ (1996)
Five years' follow-up of renal glomerular and tubular functions in heart transplant recipients
J. Heart Lung Transplant., 15 (10), 972-979

Midtvedt K, Tafjord AB, Hartmann A, Eide TC, Holdaas H, Nordal KP, Draganov B, Sodal G, Leivestad T, Fauchald P (1996)
Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection
Transplantation, 62 (1), 38-42
DOI 10.1097/00007890-199607150-00008

Nyberg G, Holdaas H, Brekke IB, Hartmann A, Norden G, Olausson M, Osterby R (1996)
Glomerular ultrastructure in kidneys transplanted simultaneously with a segmental pancreas to patients with type 1 diabetes
Nephrol. Dial. Transplant., 11 (6), 1029-1033

Publications 1983

Holdaas H (1983)
Adrenergic control of renin release
[H. Holdaas], Oslo, 1 b. (flere pag.)
BIBSYS 842007253, ISBN 82-90246-13-7